SCHEMBL5444243

SCHEMBL5444243

O=C(NCc1ccc(C(F)(F)F)cc1)Nc1ccc2[nH]ccc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTOR P42345 3/20 0.60
NAMPT P43490 2/20 0.57
PRMT3 O60678 1/20 0.54
ESR1 P03372 1/20 0.54
EPHX1 P07099 1/20 0.54
ROCK2 O75116 3/20 0.53
CHRNA7 P36544 1/20 0.51
KCNH2 Q12809 1/20 0.51
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
MCHR1 Q99705 1/20 0.50
IDH1 O75874 1/20 0.50
ROCK1 Q13464 2/20 0.49
RPS6KA5 O75582 1/20 0.49
PRKACA P17612 1/20 0.49
RPS6KB1 P23443 1/20 0.49
PRKX P51817 1/20 0.49
PRKG2 Q13237 1/20 0.49
CLK4 Q9HAZ1 1/20 0.49
SGK2 Q9HBY8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22803968 0.86 ESR1 (0.62) MTORESR1EPHX1NPC1RAB9A
SCHEMBL22803702 0.86 MTOR (0.56) MTORNAMPTESR1EPHX1ROCK2
SCHEMBL22803748 0.84 NPC1 (0.63) EPHX1ROCK2CHRNA7NPC1RAB9A
SCHEMBL22803701 0.84 CA1 (0.58) NAMPTEPHX1ROCK2ROCK1PRKACA
SCHEMBL22803700 0.84 MAOB (0.54) NAMPTEPHX1ROCK2CHRNA7KCNH2
SCHEMBL22803747 0.82 CACNA1H (0.55) NAMPTEPHX1ROCK2NPC1RAB9A
SCHEMBL5448591 0.82 ROCK1 (0.74) MTORNAMPTPRMT3ROCK2ROCK1
SCHEMBL13676156 0.81 MCHR1 (0.60) ESR1MCHR1MAOB
SCHEMBL25120846 0.80 CHRNA7 (0.50) NAMPTPRMT3EPHX1ROCK2CHRNA7
SCHEMBL17664180 0.80 IDH1 (0.61) ESR1EPHX1NPC1RAB9AIDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070078156-A1 Derivatives of n-(1h-indazolyl)-and n-(1h-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (vr1) for treatment of pain MERCK SHARP & DOHME LTD. (GB) 2007-04-05 US claimed
EP-1675587-A2 DERIVATIVES OF N-(1H-INDAZOLYL)- AND N-(1H-INDOLYL)-UREA AS WELL AS RELATED COMPOUNDS AS MODULATORS OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN MERCK SHARP & DOHME LTD. (GB) 2006-07-05 EP claimed
WO-2005028445-A2 DERIVATIVES OF N-(1H-INDAZOLYL)- AND N-(1H-INDOLYL)-UREA AS WELL AS RELATED COMPOUNDS AS MODULATORS OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN MERCK SHARP & DOHME LIMITED (GB) 2005-03-31 WO claimed
US-20070078156-A1 Derivatives of n-(1h-indazolyl)-and n-(1h-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (vr1) for treatment of pain MERCK SHARP & DOHME LTD. (GB) 2007-04-05 US disclosed
EP-1675587-A2 DERIVATIVES OF N-(1H-INDAZOLYL)- AND N-(1H-INDOLYL)-UREA AS WELL AS RELATED COMPOUNDS AS MODULATORS OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN MERCK SHARP & DOHME LTD. (GB) 2006-07-05 EP disclosed
WO-2005028445-A2 DERIVATIVES OF N-(1H-INDAZOLYL)- AND N-(1H-INDOLYL)-UREA AS WELL AS RELATED COMPOUNDS AS MODULATORS OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN MERCK SHARP & DOHME LIMITED (GB) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078156-A1 Derivatives of n-(1h-indazolyl)-and n-(1h-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (vr1) for treatment of pain CNR1, OPRL1, SIGMAR1 MTOR 3142/4885NAMPT 3460/4885PRMT3 3111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.